moclobemide has been researched along with Aging in 4 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To further investigate the possible involvement of MAO activity in changes of brain amino acid levels with aging, moclobemide and Ro 19-6327, short acting MAO-A and MAO-B inhibitors, respectively, were administered to female Wistar rats for their whole life-span." | 3.68 | The effects of lifelong treatment with MAO inhibitors on amino acid levels in rat brain. ( Cini, M; Da Prada, M; Dostert, P; Kettler, R; Marrari, P; Strolin Benedetti, M, 1990) |
| "The pharmacokinetic variability of moclobemide, a new short half-life reversible selective inhibitor of monoamine oxidase (MAO) was investigated through analysis of concentrations measured during early open clinical use." | 2.68 | Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide. ( Balant, LP; Balant-Gorgia, AE; Gex-Fabry, M, 1995) |
| " This applies particularly to the utilization of the recommended dosage range, especially in severely depressed states, and the consistent, syndrome-based combination treatment with hypnotics/sedatives or neuroleptics in the respective patient groups indicated." | 2.68 | Quality-monitoring of psychotropic drug therapy in post-marketing surveillance. Results of a drug utilization observation (DUO) study on moclobemide. ( Baier, D; Laux, G, 1997) |
| "Moclobemide is a selective inhibitor of monoamine oxidase type A." | 2.40 | Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. ( Goldberg, RJ, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gex-Fabry, M | 1 |
| Balant-Gorgia, AE | 1 |
| Balant, LP | 1 |
| Laux, G | 1 |
| Baier, D | 1 |
| Goldberg, RJ | 1 |
| Strolin Benedetti, M | 1 |
| Kettler, R | 1 |
| Marrari, P | 1 |
| Cini, M | 1 |
| Da Prada, M | 1 |
| Dostert, P | 1 |
1 review available for moclobemide and Aging
| Article | Year |
|---|---|
Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide.
Topics: Aged; Aging; Antidepressive Agents; Benzamides; Cyclohexanols; Cytochrome P-450 Enzyme Inhibitors; D | 1997 |
2 trials available for moclobemide and Aging
| Article | Year |
|---|---|
Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide.
Topics: Adult; Aged; Aged, 80 and over; Aging; Benzamides; Chromatography, Gas; Depressive Disorder; Drug In | 1995 |
Quality-monitoring of psychotropic drug therapy in post-marketing surveillance. Results of a drug utilization observation (DUO) study on moclobemide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Benzamides; Depressive Disorder; Drug Interaction | 1997 |
1 other study available for moclobemide and Aging
| Article | Year |
|---|---|
The effects of lifelong treatment with MAO inhibitors on amino acid levels in rat brain.
Topics: Aging; Amino Acids; Animals; Benzamides; Brain Chemistry; Female; Moclobemide; Monoamine Oxidase Inh | 1990 |